These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 34843581)
1. The effect of spironolactone on cardiac and renal fibrosis following myocardial infarction in established hypertension in the transgenic Cyp1a1Ren2 rat. Leader CJ; Wilkins GT; Walker RJ PLoS One; 2021; 16(11):e0260554. PubMed ID: 34843581 [TBL] [Abstract][Full Text] [Related]
2. Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat. Leader CJ; Kelly DJ; Sammut IA; Wilkins GT; Walker RJ Physiol Rep; 2020 May; 8(10):e14448. PubMed ID: 32441493 [TBL] [Abstract][Full Text] [Related]
3. Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model. Leader CJ; Moharram M; Coffey S; Sammut IA; Wilkins GW; Walker RJ PLoS One; 2019; 14(8):e0220837. PubMed ID: 31404095 [TBL] [Abstract][Full Text] [Related]
4. Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats. Ortiz RM; Graciano ML; Mullins JJ; Mitchell KD Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1584-91. PubMed ID: 17715265 [TBL] [Abstract][Full Text] [Related]
5. Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease. Jeewandara TM; Ameer OZ; Boyd R; Wyse BF; Underwood CF; Phillips JK Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):353-60. PubMed ID: 25676668 [TBL] [Abstract][Full Text] [Related]
6. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Asai M; Monkawa T; Marumo T; Fukuda S; Tsuji M; Yoshino J; Kawachi H; Shimizu F; Hayashi M; Saruta T Hypertens Res; 2004 Dec; 27(12):971-8. PubMed ID: 15894838 [TBL] [Abstract][Full Text] [Related]
7. Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats. Cezar MD; Damatto RL; Pagan LU; Lima AR; Martinez PF; Bonomo C; Rosa CM; Campos DH; Cicogna AC; Gomes MJ; Oliveira SA; Blotta DA; Okoshi MP; Okoshi K Cell Physiol Biochem; 2015; 36(4):1453-66. PubMed ID: 26160286 [TBL] [Abstract][Full Text] [Related]
8. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. Brown L; Duce B; Miric G; Sernia C J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155 [TBL] [Abstract][Full Text] [Related]
9. Activation of renal angiotensin type 1 receptor contributes to the pathogenesis of progressive renal injury in a rat model of chronic cardiorenal syndrome. Homma T; Sonoda H; Manabe K; Arai K; Mizuno M; Sada T; Ikeda M Am J Physiol Renal Physiol; 2012 Mar; 302(6):F750-61. PubMed ID: 22160776 [TBL] [Abstract][Full Text] [Related]
10. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755 [TBL] [Abstract][Full Text] [Related]
11. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473 [TBL] [Abstract][Full Text] [Related]
12. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Arai K; Tsuruoka H; Homma T Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463 [TBL] [Abstract][Full Text] [Related]
13. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996 [TBL] [Abstract][Full Text] [Related]
15. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Milliez P; Deangelis N; Rucker-Martin C; Leenhardt A; Vicaut E; Robidel E; Beaufils P; Delcayre C; Hatem SN Eur Heart J; 2005 Oct; 26(20):2193-9. PubMed ID: 16141258 [TBL] [Abstract][Full Text] [Related]
16. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Sato A; Suzuki Y; Saruta T Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346 [TBL] [Abstract][Full Text] [Related]
17. Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone. Coelho-Filho OR; Shah RV; Neilan TG; Mitchell R; Moreno H; Kwong R; Jerosch-Herold M J Am Heart Assoc; 2014 Jun; 3(3):e000790. PubMed ID: 24965024 [TBL] [Abstract][Full Text] [Related]
18. Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. Masson S; Staszewsky L; Annoni G; Carlo E; Arosio B; Bai A; Calabresi C; Martinoli E; Salio M; Fiordaliso F; Scanziani E; Rudolph AE; Latini R J Card Fail; 2004 Oct; 10(5):433-41. PubMed ID: 15470655 [TBL] [Abstract][Full Text] [Related]
19. Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage. Baumann M; Hermans JJ; Janssen BJ; Peutz-Kootstra C; Witzke O; Heemann U; Smits JF; Boudier HA J Hypertens; 2007 Dec; 25(12):2504-11. PubMed ID: 17984673 [TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial. Rajagopalan S; Dobre M; Dazard JE; Vergara-Martel A; Connelly K; Farkouh ME; Gaztanaga J; Conger H; Dever A; Razavi-Nematollahi L; Fares A; Pereira G; Edwards-Glenn J; Cameron M; Cameron C; Al-Kindi S; Brook RD; Pitt B; Weir M Circulation; 2024 Aug; 150(9):663-676. PubMed ID: 39129649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]